Novavax's Nuvaxovid COVID-19 Vaccine Conditionally Authorized In EU For Adolescents Aged 12 To 17

Biotechnology company Novavax, Inc. (NVAX) announced Tuesday that the European Commission (EC) has approved the expanded conditional marketing authorization (CMA) of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine in the European Union (EU) for adolescents aged 12 through 17.

The approval follows the positive recommendation made by the European Medicines Agency's Committee for Medicinal Products for Human Use on June 23, 2022.

The authorization was based on data from the ongoing pediatric expansion of PREVENT-19, a pivotal Phase 3 trial of 2,247 adolescents aged 12 through 17 years across 73 sites in the U.S., to evaluate the safety, effectiveness (immunogenicity), and efficacy of Nuvaxovid.

In the trial, Nuvaxovid achieved its primary effectiveness endpoint and demonstrated 80% clinical efficacy overall at a time when the Delta variant was the predominant circulating SARS-CoV-2 strain in the U.S.

The EC granted CMA for Nuvaxovid to prevent COVID-19 in individuals aged 18 and over in December 2021. In addition to the EC's expanded CMA, India has granted emergency use authorization in the 12 through 17 year-old population.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT